More positive Ph III results for imeglimin in diabetes

French drug developer Poxel (Euronext: POXEL) and Japan’s Sumitomo Dainippon Pharma (TYO: 4506) have announced today positive top-line Phase III data results for the Imeglimin TIMES 3 16-week, double-blind, placebo-controlled, randomized part of the trial for the treatment of type 2 diabetes in Japan.

Referred to as TIMES (Trials of IMeglimin for Efficacy and Safety), the imeglimin Phase III program in Japan includes three pivotal trials to evaluate imeglimin’s efficacy and safety in over 1,100 patients.

“I am very excited to contribute to the development of a new and innovative potential treatment option for Japanese patients with type 2 diabetes,” said Professor Hirotaka Watada, Department of Medicine, Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan. “Imeglimin’s safety profile combined with its unique mechanism of action that targets very important deficiencies occurring in diabetes, could be helpful for Japanese patients treated with insulin to further manage their advanced disease.”